Adverum Biotechnologies Inc.

ADVM | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.36

$0 (0.00%)

At close: Dec 9, 2025, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Sep 21, 2026

6.8

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $96.26M

1D Range

4.24 4.36

52W Range

1.78 6.07

Valuation (TTM)

PE -0.51

PB -1.73

EV/EBITDA -0.79

Valuation (NTM)

Forward PE N/A

Forward PEG 0.10

Price Target $8.90

Cash Flow

FCF Yield -143.8%

SBC Adj. FCF Yield -151.7%

SBC Impact -5.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -117.4% | -57.9%

Dil EPS 3Y | 5Y -64.8% | -46.5%

FCF 3Y | 5Y -23.7% | 0.1%

Returns

ROA -198.7%

ROE 872.8%

ROIC -433.6%

Financial Health

Net Cash

$20.25M

Current Ratio 0.65

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intra...

Sector Healthcare

Industry Biotechnology

Employees 155

IPO Date Jul 30, 2014

Website www.adverum.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Upside

+14.68%

Buy (0)

Hold (2)

Sell (0)

Analyst Details ➞